Overseas expansion of the ALS drug candidate into North America, Europe, India and China
First written in FY2023. 5 of 8 entries say "Advanced", first in 2026-03-24. Latest entry: 2026-08-19.
No other company in this theme has enough history to compare yet.
- 2026-08-19AdvancedInvestor presentation
「KP2011 (ALS overseas): Alliance discussions underway with multiple pharmaceutical companies * Advancing discussions based on the discussions with the U.S. FDA and acquisition of a U.S. use patent」
For the overseas expansion of the ALS treatment candidate, the company specifically stated that alliance discussions with multiple pharmaceutical companies were continuing. - FY2026-H1AdvancedAnnual report
「Outside Japan, we received a notice of allowance from the United States Patent and Trademark Office for “THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS AND COMPOSITION FOR TREATMENT” (reference Japanese translation: “Therapeutic Agent and Therapeutic Composition for Amyotrophic Lateral Sclerosis”).」
The company reports concrete progress in international expansion of the ALS treatment candidate through receipt of a notice of allowance from the United States Patent and Trademark Office. - FY2025RestatedAnnual report
「We are considering international expansion into North America, Europe, India and China and are advancing business development toward licensing agreements with pharmaceutical companies and other partners.」
The company continues to consider expansion of the ALS treatment candidate into North America, Europe, India and China and licensing agreements with partners. - FY2024RestatedAnnual report
「For this ALS treatment candidate, we continue to consider expansion into North America, Europe, India and China and are advancing business development toward licensing agreements with pharmaceutical companies and other partners.」
The company continues to consider expansion of the ALS treatment candidate into North America, Europe, India and China and licensing agreements with partners. - FY2023First statedAnnual report
「For this ALS treatment candidate, we continue to consider expansion into North America, Europe, India and China and are advancing business development toward licensing agreements with pharmaceutical companies and other partners.」
For KP2011, the company is considering expansion into 4 regions outside Japan and licensing agreements with pharmaceutical companies and other partners.